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Edited by Lukas HuberAbstract In avian smooth muscles, GTPcS produces a Rho ki-
nase mediated increase in PHI-1 phosphorylation and force, but
whether this correlation is causal is unknown. We examined the
eﬀect of phosphorylated PHI-1 (P-PHI-1) on force and myosin
light chain (MLC20) phosphorylation at a constant [Ca
2+]. P-
PHI-1, but not PHI-1, increased MLC20 phosphorylation and
force, and phosphorylation of PHI-1 increased the interaction
of PHI-1 with PP1c. Microcystin induced a dose-dependent
reduction in the binding of PHI-1 to PP1c. These results suggest
PHI-1 inhibits myosin light chain phosphatase by interacting
with the active site of PP1c to produce a Ca2+ independent in-
crease in MLC20 phosphorylation and force.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Phosphorylation of the 20 kDa myosin light chain (MLC20)
is the hallmark of smooth muscle contraction, and is depen-
dent on the balance between the activities of Ca2+-dependent
myosin light chain kinase (MLCK) and myosin light chain
phosphatase (MLCP) [1]. Agonist stimulation leads to an inhi-
bition of the MLCP, or Ca2+ sensitization of smooth muscles,
a G-protein mediated process, which involves many diﬀerent
signaling pathways and molecules (reviewed in [2]). MLCP is
a trimeric protein consisting of three subunits; a myosin bind-
ing subunit (MYPT1), a catalytic subunit (PP1cd), and a
20 kDa subunit of an unknown function [3]. Although little
is known about the physiologically relevant mechanism for
MLCP inhibition, two are widely accepted; (1) the phosphor-
ylation of MYPT1 [4,5] and (2) the binding of phosphatase
inhibitor proteins to the catalytic subunit of the enzyme [6,7].
We have previously demonstrated that phosphorylation of
MYPT1 does not participate in Ca2+ sensitization of avian
smooth muscle tissue [8]. These data suggest that a phospha-
tase inhibitor protein is a likely candidate to mediate Ca2+ sen-
sitization. Phosphatase inhibitor proteins are a family of*Corresponding author. Fax: +1 507 284 8566.
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doi:10.1016/j.febslet.2006.09.035proteins that speciﬁcally inhibit MLCP, and their inhibitory
potency for the phosphatase is increased upon phosphoryla-
tion [9]. They are termed inhibitor-1, in contrast to inhibitor-2
proteins that are eﬀective without phosphorylation [7]. Phos-
phatase inhibitor-1 proteins include a 17 kDa PKC and/or
Rho-kinase potentiated protein (CPI-17), phosphoprotein
holoenzyme inhibitor-1 (PHI-1), and dopamine and cAMP
regulated phosphoprotein of 32 kDa (DARPP-32) that is ex-
pressed in brain [7]. It has previously been demonstrated that
CPI-17 is not expressed in chicken smooth muscles [8,10], sug-
gesting that another inhibitor-1 type protein may serve an
analogous role. We have previously demonstrated in avian
smooth muscle that a Rho kinase mediated pathway phos-
phorylates PHI-1 during both G-protein stimulation of
skinned smooth muscles and agonist stimulation of intact
preparations [8]. However, whether PHI-1 phosphorylation
mediates Ca2+ sensitization in chicken smooth muscle is un-
known. In this study, we tested the hypothesis that phosphor-
ylation of PHI-1 leads to a Ca2+ sensitization of chicken
smooth muscle.2. Materials and methods
2.1. Preparation of phospho-PHI-1
Puriﬁed PHI-1 (Upstate Biotechnologies) was phosphorylated using
a previously described protocol [7]. Brieﬂy, PHI-1 was phosphorylated
in an assay buﬀer containing: 25 mM MOPS-NaOH pH 7.0, 10 mM
magnesium acetate, 0.3 mg/ml PHI-1 (Upstate Biotechnologies),
2 lg/ml Rho kinase (Upstate Biotechnologies), and 0.1 mM ATP for
120 min at 30 C. Phosphorylation of PHI-1 was conﬁrmed by SDS–
PAGE and western blotting using a phosphospeciﬁc antibody which
recognizes PHI-1 phosphorylated at Thr 57 [7].
2.2. Force
Following an institutionally approved IACUC protocol, the chicken
gizzard was removed and placed into cold Ca2+ free saline solution
(140 mM NaCl, 4.7 mM KCl, 1.2 mM NaH2PO4, 2.0 mM MOPS,
0.02 mM EDTA, 1.2 mM MgCl2, 5.6 mM glucose, and 0.5 mM
EGTA, pH 7.0). Small pieces of gizzard smooth muscles were cut into
strips approximately 200–700 lm long, 100–150 lm wide, and 50–
150 lm thick. As previously described [11,12], aluminum foil T-clips
were attached to each end of a gizzard strip, and then the preparation
was skinned for 30 min at 4 C in pCa9 (log10[Ca2+]) solution con-
taining 1% TritonX-100. Skinned gizzard strips were then transferred
to a mechanics workstation (Aurora Scientiﬁc, Aurora, Canada). In
pCa9 solution, one end was hooked to a force transducer (Akers AE
801 MEMSCAP, San Jose, USA) and the other to a servomotor (Aur-
ora Scientiﬁc). The tissue was stretched to L0, the length where force is
maximum as previously described [12]. Strips were then moved toblished by Elsevier B.V. All rights reserved.
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added and the resulting change in force was recorded. Finally, the tis-
sue was moved to pCa4 solution to determine the maximum Ca2+ acti-
vated force for each strip. The force at pCa9 was set to zero, and all
forces are given relative to the baseline at pCa9.2.3. Western blotting
The level of MLC20 phosphorylation was determined as previously
described [8,11–14]. After skinning, tissue was placed in a pCa6.2 solu-
tion with and without 3 lg/ml PHI-1 or P-PHI-1 for 15 min. The tis-
sues were then denatured in 10% TCA in acetone with 10 mM
dithiothreitol and stored at 80 C overnight. Samples were removed
and brought to room temperature for 1 h. After centrifuging for 1 min,
the TCA was removed and the tissues were washed three times in ace-
tone with 10 mM dithiothreitol. After the ﬁnal wash, the tissue was
dried and cut into ﬁne pieces. MLC20 was solubilized by vortexing
the tissue in 8 M urea, 20 mM Tris, 22 mM glycine, pH 8.6, 1 mM
dithiothreitol and 1 mM phenylmethylsulfonyl ﬂuoride. The samples
were run in the absence of SDS using 19:1 acrylamide:bisacrylamide
10% gels containing 40% v/v glycerol. The running buﬀer contained
20 mM Tris, 22 mM glycine, 1 mM dithiothreitol, and 1 mM thiogly-
colic acid, pH 8.6. The proteins were transferred to nitrocellulose mem-
brane and probed for MLC20 using a monoclonal anti-MLC20
antibody (Sigma). The blot was developed using alkaline phosphatase
substrate buﬀer with NitroBlue Tetrazolium and 5-bromo-4-choloro-3-
indolyl phosphate disodium salt. The level of phosphorylation of
MLC20 was determined as (MLC20  Pi/(MLC20  Pi + MLC20)) ·
100% using densitometric analysis (Scion Image). All blots were in
the linear range of the detection system [8].
The same samples were used to determine the expression of RhoA
and Rho kinase as well as PHI-1 phosphorylation. These proteins were
resolved on 29:1 acrylamide:bisacrylamide 12% SDS–PAGE, and were
then transferred to nitrocellulose membrane and probed with anti-Rho
A (Upstate Biotechnologies), anti-Rho kinase (Upstate Biotechnolo-
gies), anti-PHI-1 [7] or anti-Thr57 phosphospeciﬁc PHI-1 antibody
[7]. Blots were developed with alkaline phosphatase or chemo-lumines-
cence (Amersham).Fig. 1. Rho kinase phosphorylates PHI-1. Puriﬁed PHI-1 was phos-
phorylated by Rho kinase (see text for details). Lane 1 shows the
western blot of the puriﬁed protein, and lane 2 after Rho kinase
treatment. Western blots were probed with anti-PHI-1 and antiphos-
pho-PHI-1 antibodies. The Thr57 phosphospeciﬁc antibody only
recognized the protein after phosphorylation.
Fig. 2. Rho signaling is intact after Triton skinning. The expression of
RhoA and Rho kinase was determined in intact smooth muscle and
Triton skinned smooth muscle. As demonstrated, both RhoA and Rho
kinase are retained following skinning of the smooth muscle.2.4. Co-immunoprecipitation
Adult chicken gizzard was dissected and homogenized in lysis buﬀer
(8 M Urea, 10 mM Tris–HCl, 0.1 mM EDTA, 1X EDTA-free Com-
plete Protease Inhibitor (Roche), pH 8). The lysate was rotated for
15 min at 4 C, spun (14000 rpm) and the supernatant was collected
and stored at 80 C. Aliquots (250–300 ll) of the homogenates were
added to 1.5 ml of immunoprecipitation buﬀer (50 mM Tris–HCl (pH
8), 7 mMMgCl2, 2 mM EDTA, and 1 mM PMSF). Samples were incu-
bated on ice for 20 min under the following conditions: lysates only,
lysate + GTPcS (100 lM), and lysates + GTPcS (100 lM) + microcy-
stin LR (2 lM or 20 lM). The supernatant was rotated for 30 min at
4 C, centrifuged and separated from the precipitate. An antibody to
PP1c (Transduction Laboratories), the catalytic subunit of MLCP,
was added to the lysates and the samples were rotated overnight.
Lysates were also rotated overnight in absence of the antibody as a
negative control. Samples were centrifuged for 5 min at 4 C, and the
supernatant was removed. The antibody-protein complex was recov-
ered using Protein G sepharose beads (Amersham Biosciences). Sam-
ples were washed twice with 200 ll of immunoprecipitation buﬀer,
40 ll of SDS sample buﬀer was added, the samples were heated, and
the protein was resolved by 29:1, 12% SDS–PAGE, and Western blot-
ted with the antibody to PHI-1 [7]. Blots were developed with alkaline
phosphatase or chemi-luminescence (Amersham). Protein loading was
normalized by the IgG band, and the PHI-1 band intensity was
expressed using the following formula: [PHI-1 band intensity/(IgG
band intensity)]. Then, the intensity of the band for lysates treated with
GTPcS was set to 100%, and for the other conditions, intensities were
normalized accordingly.
2.5. Solutions
Calcium solutions were prepared using a computer program de-
signed to give a set of free ion concentrations that are adjusted for both
temperature and ionic strength [15]. The ionic strength for all solutions
was 200 mM and the experiments were carried out at a temperature of
22 C. The relaxing solution (pCa9.0) contained (in mM): 25 BES, 10
EGTA, 0.02 CaCl2, 7.2 MgCl2, 5.5 ATP, 25 creatine phosphate, 56.5KMS, pH to 7.0 with 1 M KOH and pCa4.0 solution (in mM): 25
BES, 10 EGTA, 10.2 CaCl2, 6.9 MgCl2, 5.6 ATP, 25 creatine phos-
phate, 35.8 KMS, pH to 7.0 with 1 M KOH. The solution of pCa6.2
was prepared by proportionate mixing of pCa9.0 and pCa4.0 solu-
tions.
2.6. Statistics
All values are given as the means ± S.E.M. of between three and six
experiments. Means were compared with an ANOVA and the Tukey
HSD test, and statistical signiﬁcance was taken at P < 0.05.3. Results
These experiments were designed to investigate whether
phosphorylation of PHI-1 leads to force enhancement at a
constant Ca2+, or Ca2+ sensitization, in avian smooth muscle
strips. We phosphorylated PHI-1, in vitro, with Rho kinase
using a previously published protocol [7], and conﬁrmed
PHI-1 phosphorylation with Western blotting (Fig. 1). As is
demonstrated, the anti-Thr57 phosphospeciﬁc PHI-1 antibody
[7] does not recognize the non-phosphorylated, puriﬁed pro-
tein, while after Rho kinase treatment, Thr57 phosphorylated
PHI-1 is easily detected. Further, both RhoA and Rho kinase
are retained after skinning of the avian smooth muscle strips
with TritonX-100 (Fig. 2).
The eﬀect of PHI-1 and P-PHI-1 on force in skinned gizzard
strips is demonstrated in Fig. 3 and summarized in Table 1.
When skinned gizzard strips were placed in pCa6.2 solution,
there was no increase in force compared to pCa9.0. Further
at pCa6.2, the addition of 3 lg/ml PHI-1 did not lead to force
enhancement (0.0 ± 3.4 mN/mm2, n = 5, P > 0.05). However,
at pCa6.2, 3 lg/ml of P-PHI-1 increased force by 7.4 ±
1.7 mN/mm2 (n = 5, P < 0.05), which is 50% of the level for
maximal Ca2+ activation (18.4 ± 4.4 mN/mm2, P < 0.05). In
Fig. 4. P-PHI-1 increases MLC20 phosphorylation. MLC20 phosphor-
ylation was determined in skinned gizzard strips (n = 4 for each
condition) at pCa6.2 alone, pCa6.2 with PHI-1, pCa6.2 with P-PHI-1,
as well as pCa4 (see Table 2).
Fig. 3. P-PHI-1 leads to Ca2+ sensitization. (A) A skinned gizzard strip was placed in relaxing solution (pCa9) and then transferred to pCa6.2. P-
PHI-1 (3 lg/ml) was added to the pCa6.2 and the preparation was then transferred to pCa4 solution (without PHI-1). The pCa solutions changes and
the addition of P-PHI-1 are indicated below the data trace. (B) A skinned gizzard strip was placed in relaxing solution (pCa9) and then transferred to
pCa6.2. PHI-1 (3 lg/ml) and then P-PHI-1 (1st, 3 lg/ml and then 6 lg/ml) was added to the pCa6.2 solution. The ﬁber was then transferred to pCa4
solution (without PHI-1 or P-PHI-1) and then to pCa9 solution (without PHI-1 or P-PHI-1). The pCa solutions changes and the addition of PHI-1
and P-PHI-1 are indicated below the data trace. As is demonstrated, the addition of P-PHI-1, but not PHI-1, resulted in a signiﬁcant increase in force.
Table 1
Force
(mN/mm2)
pCa 6.2 0 ± 0
pCa 6.2 + PHI-1 0.0 ± 3.4
pCa 6.2 + P-PHI-1 7.4 ± 1.7
pCa4 18.4 ± 4.4
Adult gizzard tissues were skinned with 1% Triton-X100, and stimu-
lated with pCa 6.2 alone or pCa 6.2+PHI-1, or pCa 6.2+P-PHI-1.
Force is given as the mean ± S.E.M. (n = 4–5). P-PHI-1 signiﬁcantly
(P < 0.05) increased force, but not to the level achieved with maximal
Ca2+ activation (pCa 4).
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produced an increase in force. However, unlike P-PHI-1,
which always increased force at 3 lg/ml, higher concentrations
of PHI-1 (>6 lg/ml) produced an increase in force only in 2 of
8 cases. Because the force increase at high concentrations of
unphosphorylated PHI-1 occurred infrequently, it did not
reach statistical signiﬁcance.
MLC20 phosphorylation is the hallmark of smooth muscle
contraction, and to determine if phosphorylation of PHI-1 en-
hances force by increasing MLC20 phosphorylation, we mea-
sured MLC20 phosphorylation in skinned gizzard smooth
muscle strips at pCa6.2 alone, pCa6.2 + PHI-1, or pCa6.2 +
P-PHI-1. At pCa6.2, the level of MLC20 phosphorylation in
skinned gizzard strips was 45 ± 3.9% (n = 4), and the additionof PHI-1 did not result in an increase in MLC20 phosphoryla-
tion (45 ± 1.9%, n = 4, P > 0.05). In contrast, at pCa6.2, the
addition of 3 lg/ml P-PHI-1 increased MLC20 phosphoryla-
tion to 56 ± 3% (n = 4, P < 0.05), compared to 63 ± 4.3%
(n = 3, P < 0.05) at pCa4.0 (Fig. 4 and Table 2). This result
is consistent with P-PHI-1 enhancing force by producing an
increase in MLC20 phosphorylation.
Two mechanisms have been reported for MLCP inhibition.
The ﬁrst mechanism is phosphorylation of MYPT1 [4,5,16,17],
and the second mechanism is direct binding of phosphatase
inhibitors to the catalytic subunit of the enzyme [6,7,18]. Since
we have previously demonstrated that MYPT1 phosphoryla-
tion does not change during GTPcS stimulation in avian
smooth muscles [8], this suggests that P-PHI-1 could inhibit
Table 2
MLC20 phosphorylation (%)
(%)
pCa 6.2 45 ± 4
pCa 6.2 + PHI-1 45 ± 2
pCa 6.2 + P-PHI-1 56 ± 3
pCa4 63 ± 4
Adult gizzard tissues were skinned with 1% Triton-X100, and stimu-
lated with pCa 6.2 alone, pCa 6.2 + PHI-1, or pCa 6.2 + P-PHI-1
(mean ± S.E.M., n = 3–4). The samples were then resolved and ana-
lyzed (see the text for details). P-PHI-1 stimulation signiﬁcantly
(P < 0.05) increased the level of MLC20 phosphorylation compared to
pCa 6.2, and MLC20 phosphorylation was further increased at pCa 4
(P < 0.05).
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To investigate this possibility, we utilized a co-immunoprecip-
itation protocol. The data show that PHI-1 and PP1c interact
in avian smooth muscles (Fig. 5). G-protein stimulation is
known to enhance the inhibitory potency of PHI-1 by Thr57
phosphorylation [7], which could occur if G-protein stimula-
tion enhanced the binding of PHI-1 to the catalytic subunit.
To study this, we added GTPcS, which increases PHI-1 phos-
phorylation [8], to the tissue lysates prior to co-immunoprecip-
itation. The addition of GTPcS resulted in an increase in the
interaction of PHI-1 and PP1c (P < 0.05), as evidenced by in-
crease in the signal detected after probing with PHI-1 antibody
(Fig. 5). The increase in the interaction of PHI-1 and PP1c was
not due to an increase in PP1c that is immunoprecipitated, as
PP1c was similar before and after GTPcS treatment (Supple-
mental Figure).Fig. 5. P-PHI-1 binds to the active site of PP1c. (A) Representative
immunoprecipitation with anti-PP1c antibody and Western blot for
PHI-1, which demonstrate the interaction of PP1c and PHI-1.
Immunoprecipitation was also performed following the addition of
GTPcS and microcystin to the tissue lysates. (B) Western blots were
analyzed using densitometry, and the bar graph summarizing the
results (n = 3–6). The immunoprecipitations demonstrate an interac-
tion between PP1c and PHI-1, which increases with phosphorylation
of PHI-1. The addition of Microcystin LR results in a dose dependent
decrease in the interaction of PP1c and PHI-1.To further investigate the mechanism of PHI-1 inhibition of
MLCP, we used microcystin LR. Microcystin has been demon-
strated to inhibit MLCP by binding to the active site of PP1c
[18,19], which results in a Ca2+-independent increase in MLC20
phosphorylation and force [20,21]. Lysates were treated with
microcystin after adding GTPcS. The addition of microcystin
to the co-immunoprecipitation experiments resulted in a dose
dependent reduction (P < 0.05) in the signal detected with
the PHI-1 antibody (Fig. 5), which suggests that microcystin
and PHI-1 could compete for the same binding site on PP1c.4. Discussion
G-protein stimulation has been shown to inhibit MLCP with
a resultant increase in MLC20 phosphorylation and force [22].
Phosphorylation of MYPT1 has been identiﬁed both in vivo
and in vitro as a mechanism for the inhibition of MLCP
[4,5,16,23,24]. However, a G-protein stimulation induced in-
crease in MYPT1 phosphorylation appears to be species, tissue
and agonist dependent [4,8,16,23–29]. In chicken smooth mus-
cle, we have demonstrated that MYPT1 phosphorylation does
not change during GTPcS stimulation [8]. These results suggest
that a mechanism, other than MYPT1 phosphorylation, medi-
ates Ca2+ sensitization in avian smooth muscle. One possibility
is that a phosphatase inhibitor protein could inhibit MLCP to
produce Ca2+ sensitization. Phosphorylation of protein-1
phosphatase inhibitors increases their inhibitory potency to-
wards the phosphatase [6,7], and it has been previously demon-
strated that the small phosphatase inhibitor protein, CPI-17, is
phosphorylated by both PKC and Rho kinase mediated path-
ways [29,30]. Phosphorylation of CPI-17 results in CPI-17
binding to the active site of PP1c [18], and this leads to an inhi-
bition of MLCP. However, CPI-17 expression is tissue and
species speciﬁc [10], and is not expressed in avian smooth mus-
cle tissue [8,10]. These ﬁndings raise the possibility that an-
other phosphatase inhibitor protein exists in tissues with low
levels of CPI-17 expression. PHI-1 belongs to the family of
protein 1 phosphatase inhibitors and is homologous to CPI-
17, with 29% sequence identity [7]. We have previously demon-
strated that in chicken smooth muscles, a Rho kinase mediated
pathway leads to an increase in PHI-1 phosphorylation at Thr
57 during both agonist stimulation of intact smooth muscles,
and GTPcS stimulation of skinned smooth muscle strips [8].
Phosphorylation of PHI-1 at Thr 57 is known to increase the
inhibition of MLCP [7]. Our data demonstrate that the addi-
tion of P-PHI-1 to skinned avian smooth muscle results in a
Ca2+ independent increase in force, and are similar to results
reported for rat tail arterial strips [31].
Our results are the ﬁrst demonstration that PHI-1 increases
force and mediates Ca2+ sensitization in avian smooth muscle,
and further extend the results of Deng et al. [31] by demon-
strating that the P-PHI-1 induced increase in force is concom-
itant with an increase in MLC20 phosphorylation. Further, we
have demonstrated that P-PHI-1 inhibits MLCP by interacting
with the active site of PP1c. Our data demonstrate that PHI-1
can also interact with PP1c (Fig. 5), consistent with data sug-
gesting that both PHI-1 and P-PHI-1 inhibit MLCP. However,
phosphorylation of PHI-1 increases the interaction of PHI-1
with PP1c (Fig. 5). This is consistent with the results demon-
strating that phosphorylation of PHI-1 at Thr57 increases
the inhibitory potency of PHI-1 towards MLCP [7], as well
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increases force, while higher concentrations (>6 lg/ml) of
PHI-1 can occasionally lead to force enhancement.
We have previously demonstrated that a RhoA/Rho kinase
pathway mediates the increase in MLC20 and PHI-1 phosphor-
ylation during Ca2+ sensitization of skinned and intact avian
smooth muscles [8]. Similarly, agonist stimulation of intact
smooth muscle has been demonstrated to result in PHI-1 phos-
phorylation [8,32], suggesting that PHI-1 is part of a physio-
logically relevant pathway for force regulation. In the
present study, the data demonstrate that the increase in PHI-
1 phosphorylation increases its interaction with the active site
of PP1c to inhibit MLCP and increase MLC20 phosphoryla-
tion and force.
In heart failure, there is an increase in renin angiotensin sys-
tem activity together with the increase in vascular tone, which
is thought to be an initial compensatory mechanism for the
failing heart [33]. With further progression of the disease, this
mechanism and others will contribute to remodeling of the fail-
ing heart. However, the molecular mechanism for the increase
in vascular tone in heart failure is unknown. An increase in
Angiotensin II activity could lead to a generalized increase in
PHI-1 phosphorylation, Ca2+ sensitization, and a resting vaso-
constriction, which could contribute to the increase in vascular
tone observed in heart failure.
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